Additive solutions for the Suspension of Blood Products

NHS Blood and Transplant (NHSBT) is a Special Health Authority in the NHS and is responsible for the provision of blood components and a range of associated laboratory and patient therapeutic services to hospitals in England.<br/><br/>NHSBT wishes to inform the market of prospective requirements, as far as their details are known at this time for the suspension of apheresis platelets, whole blood derived pooled platelets and specialist red cell products by the establishment of a Framework Agreement with the following Blood Establishments as beneficiaries - NHS Blood and Transplant; the Welsh Blood Service (WBS); the Northern Ireland Blood Transfusion Service (NIBTS); the Scottish National Blood Transfusion Service (SNBTS); the Australian Red Cross Lifeblood (ARCL), the New Zealand Blood Service (NZBS) and the Irish Blood Transfusion Service (IBTS). <br/><br/>Description of the goods to be purchased:<br/>Additive solution for the suspension of platelets, granulocytes and other components derived from whole blood; Additive solution for the suspension of single donor apheresis derived platelets and SAGM solution for the routine washing and re-suspension of red cells during the production of specialist blood products in accordance with the Guidelines for the Blood Transfusion Services in the UK details of which can be found at the following website www.transfusionguidelines.org/red-book ↗ <br/><br/>Supplier Engagement Meeting(s) via Microsoft TEAMS will be held in late January or early February 2023. <br/><br/>The format of the Supplier Engagement Meeting will be communicated to those organisations that respond to this PIN. <br/><br/>Expressions of interest for the Supplier Engagement activity should be submitted by email to [email protected] no later than 16:00 GMT on 13 January 2023.